Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors

Haemophilia

Volumn 23, Issue 1, 2017, Pages e50-e54

  Alvarez Roman M T ^a   Fernandez Bello, I ^a   de la Corte Rodriguez H ^a   Hernandez Moreno A L ^a   Martin Salces M ^a   Butta Coll, N ^a   Rivas Pollmar, M I ^a   Rivas Munoz S ^a   Jimenez Yuste V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DELIVERY DEVICE; DRUG HALF LIFE; HEMOPHILIA A; HUMAN; LETTER; LIFESTYLE; MIDDLE AGED; PHENOTYPE; PHYSICAL ACTIVITY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SCHOOL CHILD; YOUNG ADULT; MALE;

FACTOR VIII; HEMOPHILIA A; HUMANS; MALE;

EID: 85009135401     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13141     Document Type: Letter

References (10)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47.
2. Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol 2015; 8: 237–46.
3. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia 2014; 20: 607–15.
4. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125: 2038–44.
5. Lock J, de Bekker-Grob EW, Urhan G et al. Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. Haemophilia 2016; 22: e1–10.
6. Björkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612–8.
7. Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597–605.
8. Reiniger A, Spotts G, Low-Baselli A et al. Optimizing prophylaxis: development of an advate PK calculator and dosing medicaldevice based on a bayesian population PK model [Abstract OR07]. Haemophilia 2014; 20: 15.
9. Broderick CR, Herbert RD, Latimer J et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308: 1452–9.
10. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413–20.